Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Beta-blocker therapy in unstable severe heart failure, evidence or experience?

Literature DB >> 23239450

Beta-blocker therapy in unstable severe heart failure, evidence or experience?

C L Meuwese¹, J H Kirkels, N de Jonge, H M Nathoe, P A Doevendans, C Klöpping.

Abstract

Currently, no evidence exists on the effects of beta-receptor blocker (BRB) treatment in patients with unstable severe heart failure. When confronted with this specific patient category, clinical experience in our centre has consistently guided us to lower the dose or stop BRB therapy. To share this experience, we present three clinical case scenarios and discuss background literature motivating our approach in these patients.

Entities: Disease Species

Year: 2013 PMID： 23239450 PMCID： PMC3528855 DOI： 10.1007/s12471-012-0366-7

Source DB: PubMed Journal: Neth Heart J ISSN： 1568-5888 Impact factor: 2.380

20 in total

1. Prolongation of survival in congestive cardiomyopathy by beta-receptor blockade.

Authors: K Swedberg; A Hjalmarson; F Waagstein; I Wallentin
Journal: Lancet Date: 1979-06-30 Impact factor: 79.321

2. Beta-blocker therapy influences the hemodynamic response to inotropic agents in patients with heart failure: a randomized comparison of dobutamine and enoximone before and after chronic treatment with metoprolol or carvedilol.

Authors: Marco Metra; Savina Nodari; Antonio D'Aloia; Claudio Muneretto; Alastair D Robertson; Michael R Bristow; Livio Dei Cas
Journal: J Am Coll Cardiol Date: 2002-10-02 Impact factor: 24.094

3. Effect of chronic beta-adrenergic receptor blockade in congestive cardiomyopathy.

Authors: F Waagstein; A Hjalmarson; E Varnauskas; I Wallentin
Journal: Br Heart J Date: 1975-10

4. Beta-blocking agents in congestive heart failure: for each heart failure patient?

Authors: C Klöpping; J H Kirkels; N de Jonge
Journal: Neth Heart J Date: 2005-05 Impact factor: 2.380

Review 5. Use of combination therapy with a beta-blocker and milrinone in patients with advanced heart failure.

Authors: Douglas L Jennings; Melissa L Thompson
Journal: Ann Pharmacother Date: 2009-09-29 Impact factor: 3.154

6. The neurohormonal hypothesis: a theory to explain the mechanism of disease progression in heart failure.

Authors: M Packer
Journal: J Am Coll Cardiol Date: 1992-07 Impact factor: 24.094

7. Different responses to dobutamine in the presence of carvedilol or metoprolol in patients with chronic heart failure.

Authors: E Bollano; M Scharin Täng; A Hjalmarson; F Waagstein; B Andersson
Journal: Heart Date: 2003-06 Impact factor: 5.994

8. Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: the Metoprolol CR/XL Randomized Intervention Trial in congestive heart failure (MERIT-HF). MERIT-HF Study Group.

Authors: A Hjalmarson; S Goldstein; B Fagerberg; H Wedel; F Waagstein; J Kjekshus; J Wikstrand; D El Allaf; J Vítovec; J Aldershvile; M Halinen; R Dietz; K L Neuhaus; A Jánosi; G Thorgeirsson; P H Dunselman; L Gullestad; J Kuch; J Herlitz; P Rickenbacher; S Ball; S Gottlieb; P Deedwania
Journal: JAMA Date: 2000-03-08 Impact factor: 56.272

9. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group.

Authors: M Packer; M R Bristow; J N Cohn; W S Colucci; M B Fowler; E M Gilbert; N H Shusterman
Journal: N Engl J Med Date: 1996-05-23 Impact factor: 91.245

5. Preventing LVAD implantation by early short-term mechanical support and prolonged inodilator therapy : A case series with acute refractory cardiogenic shock treated with veno-arterial extracorporeal membrane oxygenation and optimised medical strategy.

Authors: J J Brugts; O Manintveld; A Constantinescu; D W Donker; R J van Thiel; K Nieman; L S D Jewbali; F Zijlstra; K Caliskan
Journal: Neth Heart J Date: 2014-04 Impact factor: 2.380

5 in total

Beta-blocker therapy in unstable severe heart failure, evidence or experience?

1. Prolongation of survival in congestive cardiomyopathy by beta-receptor blockade.

2. Beta-blocker therapy influences the hemodynamic response to inotropic agents in patients with heart failure: a randomized comparison of dobutamine and enoximone before and after chronic treatment with metoprolol or carvedilol.

3. Effect of chronic beta-adrenergic receptor blockade in congestive cardiomyopathy.

4. Beta-blocking agents in congestive heart failure: for each heart failure patient?

Review 5. Use of combination therapy with a beta-blocker and milrinone in patients with advanced heart failure.

6. The neurohormonal hypothesis: a theory to explain the mechanism of disease progression in heart failure.

7. Different responses to dobutamine in the presence of carvedilol or metoprolol in patients with chronic heart failure.

8. Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: the Metoprolol CR/XL Randomized Intervention Trial in congestive heart failure (MERIT-HF). MERIT-HF Study Group.

9. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group.

10. Cardiac resynchronisation improves survival in mild heart failure!

Review 1. Drug therapies in chronic heart failure: a focus on reduced ejection fraction.

2. Beta-blocking agents in cardiovascular disease; are they here to stay?

Review 3. Reviewing the Modern Therapeutical Options and the Outcomes of Sacubitril/Valsartan in Heart Failure.

4. Short-term mechanical support and pharmacotherapy, a new strategy in cardiogenic shock?

5. Preventing LVAD implantation by early short-term mechanical support and prolonged inodilator therapy : A case series with acute refractory cardiogenic shock treated with veno-arterial extracorporeal membrane oxygenation and optimised medical strategy.